Saure antipyretische Analgetika

  • Herman Hans Waldvogel

Zusammenfassung

Das chemische Grundgerüst der Salicylsäure besteht aus einem Benzolring mit einer Hydroxylgruppe sowie einer Carboxylgruppe (Phenolcarbonsäure bzw. Hydroxybenzoesäure), wobei die Orthoform (Salicylsäure) der Hydroxylgruppe, nicht aber die Meta- und Paraformen, wirksam ist. Die Salze und Ester der Salicylsäure heißen Salicylate. Derivate der Salicylsäure werden eingesetzt als
  1. 1.

    zeilschädigend wirkende Substanzen (Beispiele: das obsolete Wintergrünöl, eine Art frühes „Naturaspirin“; das bakteriostatisch wirkende Tuberkulosemittel PAS; Sulfasalazin und Mesalamin, die zur Eindämmung chronischentzündlicher Darmerkrankungen eingesetzt werden);

     
  2. 2.

    saure antipyretische Analgetika, die entweder ein Prodrug für Salicylsäure (Salsalat) oder Salicylamid (Ethenzamid, Sulfasalazin) darstellen.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur vor 1996: → CD-ROM

  1. Janssen PL, Katan MB, van Slaveren WA (1997) Acetylsalicylale and salicylates in foods. Cancer Lett 114 (1–2): 163–164PubMedCrossRefGoogle Scholar

Literatur vor 1996: → CD-ROM

  1. Batlle-Gualda E, Figueroa M, Ivorra J (1996) The efficacy and tole-rability of aceclofenac in the treatment of patients with anky-losing Spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol 7: 1200–1206Google Scholar
  2. Brogden RN, Wiseman LR (1996) Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs 52/1: 113–124CrossRefGoogle Scholar
  3. Gijgden RN, Wiseman LR (1996) Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs 52/1:113–124Google Scholar
  4. nac Indomethacin Study Group. JKornasoff D, Frerick H, Bowdler J et al. (1997) Aceclofenac is a well-tolerated alternative to napro-xen in the treatment of Osteoarthritis. Clin Rheumatol 1: 32–38CrossRefGoogle Scholar
  5. Morros R, Figueras A, Capella D (1997) Hypersensitivity vasculitis related to aceclofenac [letter] Br J Rheumatol 4: 503–504CrossRefGoogle Scholar
  6. Peréz Busquier M, Calero E, Rodríguez M (1997) Comparison of aceclofenac with piroxicam in the treatment of Osteoarthritis. Clin Rheumatol 2: 154–159CrossRefGoogle Scholar
  7. Perez Moreno JM, Puertas Montenegro M, Fernández Ruiz A et al. (1996) Hepatitis toxicam in the treatment of Osteoarthritis. Clin RheumatolGoogle Scholar
  8. Prieto de Paula JM, Romero Castro R, Villamandos Nicás YV (1997). Correspondence. Toxicidad hepática por aceclofenaco. Gastroenterol Hepatol 3: 165Google Scholar
  9. Villa Alcázar LF, de Buergo M, Rico Lenza H (1996) Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylo-sing Spondylitis: a 3 month multicenter comparative trial. Spa-nish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 7: 1194–1199Google Scholar
  10. Yamazaki R, Kawai S, Matsuzaki T et al. (1997) Aceclofenac blocks Prostaglandin E2 production following its intracellular conver-sion into cyclooxygenase inhibitors. Eur J Pharmacol 329/2–3: 181–187Google Scholar

Literatur vor1996: → CD-ROM

  1. Janssen PL, Katan MB, van Staveren WA (1997) Acetylsalicylate and salicylates in foods. Cancer Lett 114 (1–2): 163–164PubMedCrossRefGoogle Scholar
  2. Yamazaki R, Kawai S, Matsuzaki T et al. (1999) Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J Pharmacol Exp Ther 289/2: 676–681Google Scholar

Literatur vor1996: → CD-ROM

  1. Brunelle FM, Verbeeck RK (1997) Conjugation-deconjugation cycling of diflunisal via beta-glucuronidase catalyzed hydrolysis of its acyl glucuronide in the rat. Life Sci 60/22: 2013–2021CrossRefGoogle Scholar
  2. Gutthann SP, Garcia Rodríguez LA, Raiford DS (1997) Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and Perforation. Epidemiology 1: 18–24CrossRefGoogle Scholar
  3. Rich MW, Thomas RA (1997) A case of eosinophilic pneumonia and vasculitis induced by diflunisal. Chest 111/6: 1767–1769CrossRefGoogle Scholar
  4. Wang M, Dickinson RG (1998) Hepatobiliary transport of diflunisal conjugates and taurocholate by the perfused rat liver: the effect of chronic exposure of rats to diflunisal. Life Sci 62/8: 751–762CrossRefGoogle Scholar
  5. Yalcin S, Güllü IH, Tekuzman G et al. (1998) A comparison of two nonsteroidal antiinflammatory drugs (diflunisal vs. dipyrone) in the treatment of moderate to severe Cancer pain: a randomized crossover study. Am J Clin Oncol 2: 185–188CrossRefGoogle Scholar

Literatur vor1996: → CD-ROM

  1. Corrigan G, Stevens PE (2000) Review article: interstitial nephri-tis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 14/1: 1–6CrossRefGoogle Scholar
  2. Duerksen DR, Jewell LD, Mason AL et al. (1997) Co-existence of hepatitis A and adult Reye’s Syndrome. Gut 41/1: 121–124CrossRefGoogle Scholar
  3. Hämling J, Raedler A, Helmchen U, Schreiber S (1997) 5-Aminosa-licylic aeid-associated renal tubular aeidosis with decreased renal funetion in Crohn’s disease. Digestion 58/3: 304–307CrossRefGoogle Scholar
  4. Marteau P, Cellier C (1997) Effets indésirables de Facide 5-amino-salicylique. Gastroenterol Clin Biol 21/5: 377–386Google Scholar

Literatur vor1996: → CD-ROM

  1. Cross SE, Megwa SA, Benseon HA et al. (1999) Self promotion of deep tissue penetration and distribution of methylsalicylate after topical application. Pharm Res 16/3: 427–433CrossRefGoogle Scholar

Literatur vor1996: → CD-ROM

  1. Bensen W, Zizzo A (1998) Newer, safer nonsteroidal anti-inflam-matory drugs. Rational NSAID selection for arthritis. Can Farn Physician 44/101–102: 105–107Google Scholar
  2. Bjorkman DJ (1996): Nonsteroidal anti-inflammatory drug-indu-ced gastrointestinal injury. Am J Med 101 (1A): 2S–32SGoogle Scholar
  3. Bock de GH, Hermans J, Marwikjk van HWJ et al. (1996) Healthrelated quality of life assessments in Osteoarthritis during NSAID treatment. Pharm World Scie 18/4: 130–136CrossRefGoogle Scholar
  4. Checketts SR, Morgan GJ Jr (1999) Two cases of nabumetone induced pseudoporphyrie. J Rheumatol 26/12: 2703–2705Google Scholar
  5. Cook ME, Wallin JD, Thakur VD et al. (1997) Comparative effects of nabumetone, sulindac, and ibuprofen on renal function J Rheumatol 6: 1137–1144Google Scholar
  6. Davies NM (1997) Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet 33/6: 404–416Google Scholar
  7. Fleischmann RM, Flint K, Constantine G et al. (1997) A doublemasked comparison of Naprelan and nabumetone in Osteoarthritis of the knee. Naprelan Study Group. Clin Ther 4: 642–655CrossRefGoogle Scholar
  8. Gijischmann RM, Flint K, Constantine G et al. (1997) A doublemasked comparison of Naprelan and nabumetone in Osteoarthritis of the knee. Naprelan Study Group. Clin Ther 4: 642–655Google Scholar
  9. Gijón Banos J (1997) Eficacia y seguridad de la nabumetona en el tratamiento de la gonartrosis: ensayo clinico comparativo con aceclofenaco. Grupo de Estudio de Nabumetona en Artrosis de Rodilla. Med Clin (Barc) 109/4: 130–134Google Scholar
  10. Huang JQ, Sridhar S, Hunt RH (1999) Gastrointestinal safety profile of nabumetone: a meta-analysis. Am J Med 107/6A: 55–61CrossRefGoogle Scholar
  11. Krischer J, Scolari F, Kondo-Oestreicher M et al. (1999) Pseudoporphyrie induced by nabumetone. J Am Acad Dermatol 40/3: 492–493CrossRefGoogle Scholar

Literatur

  1. Demirtas RN, Oner C (1998) The treatment of lateral epicondylitis by iontophoresis of sodium salicylate and sodium diclofenac. Clin Rehabil 1: 23–29CrossRefGoogle Scholar
  2. Mitchell JA, Saunders M, Barnes PJ et al. (1997) Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation:role of arachidonic aeid. Mol Pharmacol 51/6: 907–912Google Scholar
  3. Sakitani K, Kitade H, Inoue K et al. (1997) The anti-inflammatory drug sodium salicylate inhibits nitric oxide formation induced by interleukin-ibeta at a translational step, but not at a transcriptional step, in hepatocytes. Hepatology 2: 416–420CrossRefGoogle Scholar
  4. Magro CM, Crowson AN (1999) Pseudoprophyria associated with Relafen therapy. J Cutan Phathol 26/1: 42–47CrossRefGoogle Scholar
  5. Miwa LJ, Jones JK, Pathiyal A et al. (1997) Value of epidemiologic studies in determining the true ineidence of adverse events. The nonsteroidal anti-inflammatory drug story. Arch Intern Med 157(18): 2129–2136PubMedCrossRefGoogle Scholar
  6. Schnitzer TJ, Donahue JR, Toomey EP et al. (1998) Effect of nabumetone on hemostasis during arthroscopic knee surgery. Clin Ther 1: 110–24CrossRefGoogle Scholar
  7. Varma S, Lanigan SW (1998) Pseudoporphyrie caused by nabumetone. Correspondence. Br J Dermatol 138/3: 549–550CrossRefGoogle Scholar

Literatur vor1996:s. CD-ROM

  1. Baigent C, Collins R, Appleby P et al. (1998) ISIS-2:10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous Streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 316 (7141):1337–1343PubMedCrossRefGoogle Scholar
  2. Barnes CJ, Cameron IL, Hardman WE et al. (1998) Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer 77/4: 573–580CrossRefGoogle Scholar
  3. Barnes CJ, Lee M (1998) Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114/5: 873–877CrossRefGoogle Scholar
  4. Barth W (1998) Low-dose aspirin for preeclampsia - the unresolved question. Editorial. N Engl J Med 338/11: 756–757CrossRefGoogle Scholar
  5. Blatteis CM, Sehic E (1998) Cytokines and fever. Ann N Y Acad Sci 840: 608–618PubMedCrossRefGoogle Scholar
  6. Borzak S, Cannon CP, Kraft PL et al. (1998) Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol 81/6: 678–681CrossRefGoogle Scholar
  7. Botey J, Navarro C, Marín A et al. (1988) Aspirin-induced asthma in children. Allergol Immunopathol (Madr) 3: 145–149Google Scholar
  8. Bustamante D, Paeile C, Willer JC et al. (1997) Effects of intrathecal or intracerebroventricular administration of nonsteroidal anti-inflammatory drugs on a C-fiber reflex in rats. J Pharmacol Exp Ther 281/3: 1381–1391Google Scholar
  9. Byaruhanga RN, Chipato T, Rusakaniko S (1998) A randomized controlled trial of low-dose aspirin in women at risk from preeclampsia. Int J Gynaecol Obstet 60/2: 129–135CrossRefGoogle Scholar
  10. Caspi D, Lubart E, Graff E et al. (2000) The effect of mini-dose aspirin on renal funetion and uric aeid handling in elderly patients. Arthritis Rheum 43/1: 103–108CrossRefGoogle Scholar
  11. Castano E, Dalmau M, Martí M et al. (1997) Inhibition of DNA synthesis by aspirin in Swiss 3T3 fibroblasts. J Pharmacol Exp Ther 280/1: 366–372Google Scholar
  12. Cortelazzo S, Marchetti M, Orlando E et al. (1998) Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway. Am J Hematol 57/4: 277–282CrossRefGoogle Scholar
  13. Cowburn AS, Sladek K, Soja J et ald. (1998) Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 101/4: 834–846CrossRefGoogle Scholar
  14. Essien EM, Mustard JF (1997) Inhibition of platelet adhesion to rabbit aorta by sulphinpyrazone and acetylsalicylic aeid Atherosclerosis 1: 89–95Google Scholar
  15. Flordal PA (1997) Pharmacological Prophylaxis of bleeding in surgical patients treated with aspirin. Eur J Anaesthesiol Suppl. Mar 14: 38–41CrossRefGoogle Scholar
  16. Ghahramani P, Rowland-Yeo K, Yeo WW et al. (1998) Protein binding of aspirin and salicylate measured by in vivo ultrafiltration. Clin Pharmacol Ther 63/3: 285–295CrossRefGoogle Scholar
  17. Golding J (1998) A randomised trial of low dose aspirin for Primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. Br J Obstet Gynaecol 105/3: 293–299Google Scholar
  18. Gordon J, Ramsay R, Treasure J (1997) Use of aspirin to facilitate vomiting in a young woman with bulimia nervosa: a case report. Int J Eat Disord 2: 201–203CrossRefGoogle Scholar
  19. Gregorini L, Marco J (1997) Ticlopidine and aspirin interactions. Heart 77/1: 11–12Google Scholar
  20. Groppetti A, Braga PC, Biella G et al. (1988) Effect of aspirin on Serotonin and met-Google Scholar
  21. Guazzi MD, Campodonico J, Celeste F et al. (1998) Antihypertensive efficacy of angiotensin Converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther 63/1: 79–86CrossRefGoogle Scholar
  22. Hida T, Leyton J, Makheja AN, Ben-Av P et al. (1998) Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res 2A: 775–782Google Scholar
  23. Hirschowitz BI, Lanas A (1998) Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology 114/5: 883–892CrossRefGoogle Scholar
  24. Hopper S, Pierce M (1998) Aspirin after myocardial infarction: the importance of over-the-counter use. Farn Pract S1: S10–13Google Scholar
  25. Hugues FC, Lacoste JP, Danchot J et al. (1997) Repeated doses of combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine. Headache 37/7: 452–454CrossRefGoogle Scholar
  26. Husain S, Andrews NP, Mulcahy D et al. (1998) Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 97/8: 716–720CrossRefGoogle Scholar
  27. James DN, Fernandes JR, Calder I et al. (1997) Low-dose aspirin and intracranial surgery. A survey of the opinions of Consultant neuroanaesthetists in the UK.Anaesthesia 52/2: 169–172CrossRefGoogle Scholar
  28. Kroenke K, Gooby-Toedt D, Jackson JL (1998) Chronic medications in the perioperative period. South Med J 91/4: 358–364CrossRefGoogle Scholar
  29. Kronmal RA, Hart RG, Manolio TA et al. (1998) Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group. Stroke 5: 887–894CrossRefGoogle Scholar
  30. Lora M, Morisset S, Menard HA et al. (1997) Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Prostaglandins Leukot Essent Fatty Acids 56/5: 361–367CrossRefGoogle Scholar
  31. Milewski M, Mastalerz L, Nizankowska E et al. (1998) Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sen-sitive asthma. J Allergy Clin Immunol 101/5: 581–586CrossRefGoogle Scholar
  32. Mitchell JA, Saunders M, Barnes PJ et al. (1997) Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of ara-chidonic acid. Mol Pharmacol 51/6: 907–912Google Scholar
  33. Nakajima H, Takami H, Yamagata K (1997) Aspirin effects on colonic mucosal bleeding: implications for colonic biopsy and polypectomy. Dis Colon Rectum 40/12: 1484–1488CrossRefGoogle Scholar
  34. Norrish AE, Jackson RT, McRae CU (1998) Non-steroidal antiinflammatory drugs and prostate cancer progression. Int J Cancer 77/4: 511–515CrossRefGoogle Scholar
  35. Nye EJ, Hockings GI, Grice JE et al. (1997) Aspirin inhibits vaso-pressin-induced hypothalamic-pituitary-adrenal activity in normal humans. J Clin Endocrinol Metab 82/3: 812–817CrossRefGoogle Scholar
  36. Oberle S, Polte T, Abate A et al. (1998) Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res 82/9: 1016–1020CrossRefGoogle Scholar
  37. Oosterga M, Anthonio RL, de Kam PJ et al. (1998) Effects of aspirin on angiotensin-converting enzyme inhibition and left ventri-cular dilation one year after acute myocardial infarction. Am J Cardiol 81/12: 1178–1181CrossRefGoogle Scholar
  38. Palatnick W, Tenenbein M (1998) Aspirin poisoning during pregnancy: increased fetal sensitivity. Am J Perinatol 1:39–41CrossRefGoogle Scholar
  39. Pini LA, Vitale G, Sandrini M (1997) Serotonin and opiate involve-ment in the antinociceptive effect of acetylsalicylic acid. Phar-macology 54/2: 84–91Google Scholar
  40. Price KS, Thomson DM (1997) Localized unilateral periorbital edema induced by aspirin. Ann Allergy Asthma Immunol 79/5:20–422.Google Scholar
  41. Romanovsky AA, Székely M (1998) Fever and hypothermia: two adaptive thermoregulatory responses to systemic inflammation Med Hypotheses 50/3: 219–226CrossRefGoogle Scholar
  42. adaptive thermoregulatory responses to systemic inflammation Med Hypotheses 50/3: 219–226 Ruffin MT 4th, Krishnan K, Rock CL (1997) Suppression of human colorectal mucosal Prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 89/15: 1152–1160CrossRefGoogle Scholar
  43. Sabouni F, Firouzi M, Taghikhani M et al. (1998) Neurite outgrowth of dorsal root ganglia is delayed and arrested by aspirin. Biohem Biophys Res Commun 248/1: 165–167CrossRefGoogle Scholar
  44. Sandler RS, Galanko JC, Murray SC et al. (1998) Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 114/3: 441–447CrossRefGoogle Scholar
  45. Siegmund W, Hoffmann C, Zschiesche M et al. (1998) Relative bio-availability of rapidly dispersing, piain, and microencapsuled acetylsalicylic acid tablets after single dose administration. Int J Clin Pharmacol Ther 36/3: 133–138Google Scholar
  46. Singh AK, Trotman BW (1998) Use and safety of aspirin in the chemoprevention of colorectal cancer. J Assoc Acad Minor Phys 9/2: 40–44Google Scholar
  47. Sola Alberich R, Jammoul A, Masana L (1997) Henoch-Schönlein purpura associated with acetylsalicylic acid. Letter. Ann Intern Med 126/8: 665CrossRefGoogle Scholar
  48. Stürmer T, Glynn RJ, Lee IM et al. (1998) Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Ann Intern Med 128/9: 713–720CrossRefGoogle Scholar
  49. Subbegowda R, Frommel TO (1998) Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res 58/13: 2772–2776Google Scholar
  50. Tharion G, Bhattacharji S (1997) Aspirin in Chloroform as an effective adjuvant in the management of chronic neurogenic pain. Arch Phys Med Rehabil 78/4: 437–439CrossRefGoogle Scholar
  51. van Sonnenberg E, Wittich G (1998) Hemoptysis during lung biopsy after aspirin. AJR Am J Roentgenol 171/1: 261CrossRefGoogle Scholar
  52. Willoughby S, Pearson TC (1998) The use of aspirin in poly-cythaemia vera and primary thrombocythaemia. Blood Rev 1: 12–22CrossRefGoogle Scholar
  53. Yosipovitch G, Ademola J, Lui P et al. (1997) Topically applied aspirin rapidly decreases histamine-induced itch. Acta Derm Vene-reol 77/1: 46–48Google Scholar
  54. Younossi ZM, Strum WB, Schatz RA et al. (1997) Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Dig Dis Sci 42/1: 79–82CrossRefGoogle Scholar

Literatur vor 1996: → CD-ROM

  1. Lequesne M, Fannius J, Reginster JY et al. (1997) Floctafenin vs. acetaminophen for pain control in patients with Osteoarthritis in the lower limbs. Franco-Belgian Task Force. Rev Rhum Engl Ed 64/5: 327–333Google Scholar
  2. Giuseppe P, Antonino R, Alessandro DB et al. (1997) Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 78/1: 74–78CrossRefGoogle Scholar

Literatur vor 1996: → CD-ROM

  1. Chen Q, Olney JW, Lukasiewicz PD et al. (1998) Fenamates protect neurons against ischemic and excitotoxic injury in chick embryo retina. Neurosci Lett 242(3): 163–166PubMedCrossRefGoogle Scholar
  2. Farrugia G, Nitecki S, Harty GJ et al. (1998) The effect of flufenamic acid on gastrointestinal myoelectrical activity and transit time in dogs. Gut 42/2: 258–265CrossRefGoogle Scholar
  3. Hippius M, Uhlemann C, Smolenski U et al. (1998) In vitro investigations of drug release and penetration-enhancing effect of ultrasound on transmembrane transport of flufenamic acid.Int J Clin Pharmacol Ther 36/2: 107–111Google Scholar

Literatur bis 1996: → CD-ROM

  1. Cryer B, Feldman M (1998) Cyclooxygenase-i and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104/5: 413–421CrossRefGoogle Scholar
  2. Dasgupta A, Emerson L (1996) Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. Ther Drug Monit 6: 654–659CrossRefGoogle Scholar
  3. McGurk KA, Remmel RP, Hosagrahara VP et al. (1996) Reactivity of mefenamic acid 1-o-acyl glucuronide with proteins in vitro and ex vivo. Drug Metab Dispos 8: 842–849Google Scholar
  4. Nagele F, Lockwood G, Magos AL (1997) Randomised placebo controlled trial of mefenamic acid for premedication at outpatient hysteroscopy: a pilot study. Br J Obstet Gynaecol 104/7: 842–824Google Scholar
  5. Nagele F, Lockwood G, Magos AL (1997) Randomised placebo controlled trial of mefenamic acid for premedication at outpatient hysteroscopy: a pilot study. Br J Obstet Gynaecol 104/7: 842–844Google Scholar
  6. Sato J, Kudo N, Owada E et al. (1997) Urinary excretion of mefenamic acid and its metabolites including their esterglucuronides in preterm infants undergoing mefenamic acid therapy. Biol Pharm Bull 4: 443–445CrossRefGoogle Scholar
  7. Uyemura SA, Santos AC, Mingatto FE et al. (1997) Diclofenac sodium and mefenamic acid: potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch Biochem Biophys 342/2: 231–235CrossRefGoogle Scholar

Siehe CD-ROM

  1. Radi S, Broux F, Noblet C et al. (1999) Danger du nifluril pendant la grossesse: un cas d’insuffisance renale chronique á début antenatal. Arch Pediatr 6(3): 338–339PubMedCrossRefGoogle Scholar

Literatur vor 1996: → CD-ROM

  1. Haliotis FA, Tzortzinis AA, Papanastasiou DA (1997) Use of tolfenamic acid in febrile children with and without glucose-6-phos-phate dehydrogenase deficiency. Int J Clin Pharmacol Ther 35/3: 103–106Google Scholar
  2. Krymchantowski AV, Adriano M, Fernandes D (1999) Tolfenamic acid decreases migraine recurrence when used with Sumatriptan. Cephalalgia 19/3: 186–187CrossRefGoogle Scholar
  3. Myllylä VV, Havanka H, Herrala L et al. (1998) Tolfenamic acid rapid release vs. Sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 38/3: 201–207CrossRefGoogle Scholar
  4. Sidelmann UG, Christiansen E, Krogh L et al. (1997) Puriflcation and 1H NMR spectroscopic characterization of phase II metabolites of tolfenamic acid. Drug Metab Dispos 6: 725–731Google Scholar

Literatur vor 1996: → CD-ROM

  1. Fontana RK, McCashland TM, Benner KG et al. (1999) Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg 5/6: 480–484Google Scholar
  2. Friedman MA, Woodcock J, Lumpkin MM et al. (1999) The safety of newly approved medicines: do recent markt removals mean there is a problem? JAMA 281/18: 1728–1734CrossRefGoogle Scholar
  3. Hunger EB, Johnston PE, Tanner G et al. (1999) Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol 94/8: 2299–2301Google Scholar
  4. Johnson GH, Van Wagoner JD, Brown J et al. (1997) Bromfenac sodium, acetaminophen/oxycodone, ibuprofen, and placebo for relief of postoperative pain. Clin Ther 3: 507–519CrossRefGoogle Scholar
  5. Moses PL, Schroeder B, Alkhatib O et al. (1999) Severe hepatotoxicity associated with bromfenac sodiu, Am J Gastroenterol 94/5: 1393–1396CrossRefGoogle Scholar
  6. Rabkin JM, Smith MJ, Orloff SL et al. (1999) Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 33/9: 945–947CrossRefGoogle Scholar

Literatur bis 1996: s. CD-ROM

  1. Akriviadis EA, Hatzigavriel M, Kapnias D et al. (1997) Treatment of biliary colic with diclofenac: a randomized, double-blind, pla-cebo-controlled study. Gastroenterology 113/1: 225–231CrossRefGoogle Scholar
  2. Bhoagaraju A, Nazeer S, Al-Baghdadi Y et al. (1999) Diclofenac-associated hepatitis. South Med J 92/7: 711–713CrossRefGoogle Scholar
  3. Bort R, Mace K, Boobis A et al. (1999) Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58/5: 787–796CrossRefGoogle Scholar
  4. Bougie D, Johnson ST, Weitekamp LA et al. (1997) Sensitive to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood 90/1: 407–413Google Scholar
  5. Cardoso MM, Carvalho JC. Amaro AR et al. (1998) Small doses of intrathecal morphine combined with systemic diclofenac for postoperative pain control after cesarean delivery. Anesth Anaig 86/3: 538–541Google Scholar
  6. Colbert S, O’Hanlon DM, Galvin S et al. (1999) The effect of rectal diclofenac on pruritus in patients receiving intrathecal morphine. Anaesthesia 54/10: 948–952CrossRefGoogle Scholar
  7. De Quir S, O’Hanlon DM, Galvin S et al. (1999) The effect of rectal diclofenac on pruritus in patients receiving intrathecal morphine. Anaesthesia 54/10: Farrell GC (1997) Drug-induced hepatic injury. J Gastroenterol Hepatol 12/9–10: S242–S250Google Scholar
  8. Gehling M (1997) Intramuskuläre Injektionen von Diclofenac Dtsch Med Wochenschr 122/39: 1195–1196Google Scholar
  9. Goei The HS, Lund B, Distel MR et al. (1997) A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of Osteoarthritis of the knee. Osteoarthritis Cartilage 5/4) 283–288Google Scholar
  10. Grace D, Rogers J, Skeith M et al. (1999) Topical diclofenac vs. placebo: a double blind, randomized clinical trial in patients with Osteoarthritis of the knee. J Rheumatol 26/12: 2659–2663Google Scholar
  11. Jones AL, Latham T, Shallcross TM et al. (1998) Fulminant hepatic failure due to diclofenac treated successfully by orthotopic liver transplantation. Transplant Proc 30/1: 192–194CrossRefGoogle Scholar
  12. Labelle H, Guibert R (1997) Efficacy of diclofenac in lateral epicondylitis of the elbow also treated with immobilization. The University of Montreal Orthopaedic Research Group. Arch Farn Med 6/3: 257–262CrossRefGoogle Scholar
  13. LeLoet X, Dreiser RL, Le Gros V et al. (1997) Therapeutic equivalence of diclofenac sustained-released 75 mg tablets and diclofenac enteric-coated 50 mg tablets in the treatment of painful Osteoarthritis. Int J Clin Pract 51/6: 389–393Google Scholar
  14. Matz H, Bialy-Golan A, Brenner S (1997) Diclofenac: a new trigger of pemphigus vulgaris? Dermatology 195/1: 48–49CrossRefGoogle Scholar
  15. McNeely, Goa KL (1999) Diclofenac-potassium in migraine: a review. Drugs 57/6: 991–1003CrossRefGoogle Scholar
  16. Mercadante S, Sapio M, Caligara M et al. (1997) Opioid-sparing effect of diclofenac in cancer pain. J Pain Symptom Manage 14/1: 15–20CrossRefGoogle Scholar
  17. Mori E, Ikeda H, Ueno T, Kai H et al. (1997) Vasospastic angina induced by nonsteroidal anti-inflammatory drugs. Clin Cardiol 7: 656–688CrossRefGoogle Scholar
  18. Nergelius G, Vinge E, Bengtsson et al. (1997) No effect of diclofenac on the pharmacokinetics of cloxacillin. Pharmacol Toxicol 81/1: 26–30CrossRefGoogle Scholar
  19. Niemi TT, Taxell C, Rosenberg PJ (1997) Comparison of the effect of intravenous ketoprofen, ketorolac and diclofenac on platelet function in volunteers. Acta Anaesth Scand 41/10: 1353–1358CrossRefGoogle Scholar
  20. Ohana M, Hajiro K, Takakuwa H et al. (1997) Recovery from dicl-ofenac-induced hypersensitive fulminant hepatitis and Prostaglandins. Dig Dis Sci 42/110: 2031–2032CrossRefGoogle Scholar
  21. Papworth J, Colville-Nash P, Alam C et al. (1997) The depletion of substance P by diclofenac in the mouse. Eur J Pharmacol 325/2–3: R1–R2CrossRefGoogle Scholar
  22. Revai T, Harmos G (1999) Nephrotic Syndrome and acute inter-stitial nephritis associated with the use of diclofenac. Wien Klin Wochenschr 111/13: 523–524Google Scholar
  23. Scott RM, Jennings PN (1997) Rectal diclofenac analgesia after abdominal hysterectomy. Aust N Z J Obstet Gynaecol 37/1: 112–114CrossRefGoogle Scholar
  24. Sharir M (1997) Exazerbation of asthma by topical diclofenac. Letter. Arch Ophthalmol 115/2: 294–295CrossRefGoogle Scholar
  25. Sandelin J, Harilainen A, Crone H et al. (1997) Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. Scand J Rheumatol 26/4: 287–292CrossRefGoogle Scholar
  26. Shrivastava MP, Makde SD, Paranjpe BD (1997) Interaction of ciprofloxacin with diclofenac and paracetamol in relation to it’s epileptogenic effect. Indian J Physiol Pharmacol 41/2: 164–166Google Scholar
  27. Vila Santasuana A, Cid Panella R, Roure Nuez C et al. (1997) Hepatits aguda por diclofenaco. Letter. Gastroenterol Hepatol 20/3: 164–165Google Scholar

Literatur bis 1996: → CD-ROM

  1. Casey R,Zadra J,Khonsari H (1997) A comparison of etodolac (Ultradol) with acetaminophen plus codeine (Tylenol £3) in Controlling post-surgical pain in vasectomy patients. Curr Med Res Opin 13(10): 555–563PubMedCrossRefGoogle Scholar
  2. Dvornik DM (1997) Tissue selective Inhibition of Prostaglandin biosynthesis by etodolac. J Rheumatol S47: 40–47Google Scholar
  3. Lightfoot R (1997) Comparison of the efficacy and safety of etodolac and Piroxicam in patients with rheumatoid arthritis Etodolac Study 326 Rheumatoid Arthritis Investigators Group J Rheumatol S47: 10–16’Google Scholar
  4. Neustadt DH (1997) Double blind evaluation of the long-term ettects of etodolac vs. Ibuprofen in patients with rheumatoid arthritis. J Rheumatol S47: 17–22Google Scholar
  5. Ogiso T, Kitagawa T, Iwaki M (1997) Pharmacokinetic analysis of enterohepatic circulation of etodolac and effect of hepatic and renal injury on the pharmacokinetics. Biol Pharm Bull 20/4: 405–410CrossRefGoogle Scholar
  6. Schnitzer TJ, Constantine G (1997) Etodolac (Lodine) in the treatment of Osteoarthritis: recent studies. J Rheumatol S47: 23–31Google Scholar
  7. Spencer-Green G (1997) Low dose etodolac in rheumatoid arthritis: a review of early studies. J Rheumatol S47: 3–9 und 48–50Google Scholar
  8. Wilcox GM, Porensky RS (1997) Acute Colitis associated with etodolac. J Clin Gastroenterol 1: 367–368CrossRefGoogle Scholar

Literatur vor 1996: s. CD-ROM

  1. Moore RA, Tramer MR, Carroll D et al. (1998) Quantitative syste-matic review of topically applied non-steroidal anti-inflamma-tory drugs. BMJ 316(7128): 333–338PubMedCrossRefGoogle Scholar

Literatur bis 1996: → CD-ROM

  1. Arnaud B, Trinquand C (1997) Étude en double insu sur 3 groupes paralleles de deux formulations d’indométhacine à 0,1% et du diclofenac à 0,1% dans la prévention et le contrôle de l’inflammation apres Chirurgie de la cataracte. J Fr Opthalmol 20/3: 183–188Google Scholar
  2. Bednarcyzk EM; Furniss SM; Green JA et al. (1997) Evaluation of the indomethacin-nitroglycerin interaction with posi-tron-emission tomography J Cardiovasc Pharmacol 30/6: 731–733CrossRefGoogle Scholar
  3. Chan TY (1997) Prolongation of Prothrombin time with the use of indomethacin and warfarin. Br J Clin Pract 51/3: 177–178Google Scholar
  4. Huang WT, Lin MT, Won SJ (1997) Staphylococcal enterotoxin A-induced fever is associated with increased circulating levels of cytokines in rabbits. Infect Immun 65/7: 2656–2662Google Scholar
  5. Jeanfils S, Joly P, Young P et al. (1997) Indomethacin treatment of eighteeen patients with Sweet’s Syndrome. J Am Acad Dermatol 36(3Pt1): 436–443PubMedCrossRefGoogle Scholar
  6. Kovarik JM, Mueller EA, Gerbeau C et al. (1997) Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. J Clin Pharmacol 37/4: 336–343CrossRefGoogle Scholar
  7. Linthorst AC, Reul JM (1998) Brain neurotransmission during peripheral inflammation. Ann NY Acad Sci 840: 139–152PubMedCrossRefGoogle Scholar
  8. Mignat C (1997) Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 4: 267–278CrossRefGoogle Scholar
  9. Parrott RF, Vellucci SV, Goode JA et al. (1997) Interrelated adrenocortical and neurohypophysical responses associated with fever in endotoxin-treated pigs. Am J Physiol 273(3Pt2): R1046–1052PubMedGoogle Scholar
  10. Scheuren N, Neupert W, Ionac M et al. (1997) Peripheral noxious Stimulation releases spinal PGE2 during the first phase in the formalin assay of the rat. Life Sci 60/21: PL295–300Google Scholar
  11. Waller J, Siney L, Hoult JR et al. (1997) A study of neurokinins and other oedema-inducing mediators and mechanisms in thermal injury. Clin Exp Pharmacol Physiol 11: 861–863CrossRefGoogle Scholar

Literatur bis 1996: → CD-ROM

  1. Bailey R, Sinha C, Burgess LP (1997) Ketorolac tromethamine and hemorrhage in tonsillectomy: a prospective, randomized, double-blind study. Laryngoscope 107/2: 166–169CrossRefGoogle Scholar
  2. Brook JW, Boike A, Zema RL et al. (1997) The anti-inflammatory action of locally injected ketorolac. J Am Podiatr Med Associ 87/10: 460–465Google Scholar
  3. Cold JA, ZumBrunnen TL, Simpson MA et al. (1998) Increased lithium serum and red blood cell concentration during ketorolac coadministration. J Clin Psychopharmacol 1: 33–37CrossRefGoogle Scholar
  4. Cordero JA, Alarcon L, Escribano E (1997) A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. J Pharm Sci 86/4: 503–508CrossRefGoogle Scholar
  5. Di Trolio RN, Sing RF, Bates GM (1999) Use of ketorolac in renal colic. J Am Osteopath Assoc 99/11: 589–590Google Scholar
  6. Feldman HI, Kinman JL, Berlin JA et al. (1997) Parenteral ketorolac: the risk of acute renal failure. Ann Intern Med 126/3: 193–199CrossRefGoogle Scholar
  7. Forrest JB, Heitlinger EL, Revell S (1997) Ketorolac for postoperative pain management in children. Drug Saf 5: 309–329CrossRefGoogle Scholar
  8. Foster PN, Williams JG (1997) Bradycardia following intravenous ketorolac in children. Eur J Anaesthesiol 3: 307–309CrossRefGoogle Scholar
  9. García Rodríguez LA, Cattaruzzi C, Troncon MG et al. (1998) Risk of hospitalisation for Upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calzium antagonists, and other antihypertensive drugs. Arch Intern Med 158/1: 33–39CrossRefGoogle Scholar
  10. Gerancher JC, Waterer R,Middleton J (1997) Transient paraparesis after postdural puneture spinal hematoma in a patient reeeiving ketorolac. Anesthesiology 86/2: 490–494CrossRefGoogle Scholar
  11. Gillis JC, Brogden RN (1997) Ketorolac. A reappraisal of its pharmacodynamic and pharmaeokinetie properties and therapeutic use in pain management. Drugs 53/1: 139–188CrossRefGoogle Scholar
  12. Gordon RL (1998) Prolonged central intravenous ketorolac continuous infusion in a cancer patient with intractable bone pain. Ann Pharmacother 32/2: 193–196CrossRefGoogle Scholar
  13. Goyal SB, Goyal RS (1998) Ketorolac tromethamine-induced acute pancreatitis. Letter. Arch Intern Med 158/4: 411CrossRefGoogle Scholar
  14. Handley DA, Cervoni P, McCray JE et al. 1998) Preclinical enantioselective pharmacology of (R)- and (S)-ketorolac. J Clin Phar-macol 38/2S: 25S–35S.CrossRefGoogle Scholar
  15. Hamunen K, Maunuksela EL, Sarvely J et al. (1999) Stereoselective pharmaeokinetics of ketorolac in children, adolescents and adults. Acta Anaesthesiol Scand 43/10: 1041–1046CrossRefGoogle Scholar
  16. Harden RN, Rogers D, Fink K et al. (1998) Controlled trial of ketorolac in tension-type headache. Neurology 50/2:507–5009CrossRefGoogle Scholar
  17. Hennessy S, Kinman JL, Berlin JA et al. (1997) Lack of hepatotoxic effects of parenteral ketorolac in the hospital setting. Arch Intern Med 157/21: 2510–25514CrossRefGoogle Scholar
  18. Hughes A, Wilcock A, Corcoran A (1997) Ketorolac: continuous subeutaneous infusion for cancer pain. Correspondence. J Pain Symptom Manage 6: 313–316Google Scholar
  19. Jaquenod M, Rönnhedh C, Cousins MJ et al. (1998) Factors influencing ketorolac-associated perioperative renal dysfunetion. Anesth Anaig 86/5: 1090–1097Google Scholar
  20. Lieh-Lai MW, Kauffman RE, Uy HG et al. (1999) A randomized comparison of ketorolac tromethamine and morphine for postoperative analgesia in eritieally ill children. Crit Care Med 27/12: 2786–2791CrossRefGoogle Scholar
  21. Marín-Bertolín S, De André J, González-Martínez R et al. (1997) A controlled, randomized, double-blind study of ketorolac for postoperative analgesia after plastic surgery. Ann Plast Surg 38/5: 478–484CrossRefGoogle Scholar
  22. Myles PS, Power I (1998) Does ketorolac cause postoperative renal failure: how do we assess the evidence. Editorial IV. Brit J Ana-esth 80/4: 420–421CrossRefGoogle Scholar
  23. Otti T, Weindel M, Bastiani B (1997) Ketorolac induce acute reversible hearing loss in a patient maintained on CAPD. Correspondence. Clin Nephrol 47/3: 208–209Google Scholar
  24. Reuben SS, Connelly NR, Lurie S et al. (1998) Dose-response of ketorolac as an adjunet to patient-controlled analgesia morphin in patients after spinal fusion surgery. Anesth Anaig 87/1: 98–102Google Scholar
  25. Steinberg RB, Reuben SS, Gardner G (1998) The dose-response relationship of ketorolac as a component of intravenous regional anesthesia with lidocain. Anesth Anaig 86/4: 791–793Google Scholar

Literatur vor 1996: → CD-ROM

  1. Deneke J, LuckowV, Guserle et al. (1998) Transsynovial kinetics of lonazolac and its hydroxy metabolige in synovitis patients. Int J Pharmacol Ther 36/8: 418–419Google Scholar

Literatur bis 1996: → CD-ROM

  1. Cook ME, Wallin JD, Thakur VD et al. (1997) Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 24/6: 1137–1144Google Scholar
  2. Davies NM,Watson MS (1997) Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacol 32/6: 437–459Google Scholar
  3. Giardello FM, Spannhake EW, DuBois RN et al. (1998) Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 43/2: 311–3316Google Scholar
  4. Han EK, Arber N, Yamamoto H et al. (1998) Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast Carcinoma cell lines. Breast Cancer Res Treat 48/3: 195–203CrossRefGoogle Scholar
  5. Tokumine F, Sunagawa T, Shiohira Y et al. (1999) Drug-associated cholelithiais: a case of sulindac stone formation and the incorporation of sulindac metabolites into the gallstones. Am J Gastroenterol 94/8: 2285–2288CrossRefGoogle Scholar
  6. Lampela ES, Nuutinen LH, Ala.Kokko TI et al. (1999) Placental transfer of sulindac, sulindac sulfide, and indomethacin in a human placental perfusion model. Am J Obstet Gynecol 18o(1Pt1): 174–180CrossRefGoogle Scholar
  7. Mahmoud NN, Boolbol SK, Dannenberg AJ et al. (1998) The sulfide metabolite of sulindac prevents tumors and restores ent-erocyte apoptosis in a murine model of familial adenomatous Polyposis. Carcinogenesis 1: 87–91CrossRefGoogle Scholar
  8. Peek MJ, McCarthy A, Kyle P et al. (1997) Medical amnioreduetion with sulindac to reduce cord complications ini monoamniotic twins. Am J Obstet Gynecol 176/2: 334–336CrossRefGoogle Scholar
  9. Piazza GA, Alberts DS, Hixson LJ et al. (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing Prostaglandin levels. Cancer Res 57/14: 2909–2915Google Scholar
  10. Reddy BS, Kawamori T, Lubet R et al. (1999) Chemopreventive effect of S-methylmethane thiosulfate and sulindac administered together during the promotion/progression stages of colon carcinogenesis. Carcinogenesis 20/8: 1645–1648CrossRefGoogle Scholar
  11. Thompson HJ, Jiang C, Lu J et al. (1997) Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 57/2: 267–271Google Scholar
  12. Walker AM (1997) Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum 40/2: 201–208CrossRefGoogle Scholar
  13. Yoon KH, Ng SC (1998) A case of sulindac-induced enteropathy resulting in jejunal Perforation. Ann Acad Med Singapore 1: 116–119Google Scholar

Literatur bis 1996: s. CD-ROM

  1. Krivoy N, Azzam Z, Oren I et al. (1997) Interstitial nephritis, toxic epidermal necrolysis and liver dysfunction associated to fenbufen. Clin Rheumatol 16/5: 489–490CrossRefGoogle Scholar

Literatur bis 1996: → CD-ROM

  1. Martens M (1997) Efficacy and tolerabilits of a topical NSAID patch (local action transcutaneous flurbiprofen) and oral diclofeanc in the treatment of soft-tissue rheumatism. Clin Rheumatol 1: 25–31CrossRefGoogle Scholar
  2. Oelkers R, Neupert W, Williams et al. (1997) Disposition and effec-ts of flurbiprofen enantiomers in human serum and blister fluid. Br J Clin Pharmacol 43/2: 145–153Google Scholar

Literatur bis 1996: → CD-ROM

  1. Ananda JV, Varvarigou A, Beharry K et al. (1997) Pharmacokine-tics and protein binidung of intravenous ibuprofen in the pre-mature newborn infant. Acta Paediatr 86/3: 289–293CrossRefGoogle Scholar
  2. Bernard GR, Wheeler AP, Russell JA et al. (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336/13: 912–918CrossRefGoogle Scholar
  3. Cook ME, Wallin JD, Thakur VD et al. (1997) Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 24/6: 1137–1144Google Scholar
  4. Cryer B, Feldman M (1998) Cyclooxygenase-i and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104/5: 413–421CrossRefGoogle Scholar
  5. Dirig DM, Isakson P, Yaksh TL (1998) Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J Pharmacol Exp Ther 285/3: 1031–1038Google Scholar
  6. Hawkey CJ, Cullen DJ, Pearson G et al. (2000) Ibuprofen vs. other non-steroidal anti-inflammatory drugs: use in general practice and patient perception. Aliment Pharmacol Ther 14/2: 187–191CrossRefGoogle Scholar
  7. Kellstein DE, Lipton RB, Geetha R et al. (2000) Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind placebo-con-trolled, dose-ranging study. Cephalalgia 20: 233–243PubMedCrossRefGoogle Scholar
  8. Mixter CG 3rd,Meeker LD, Gavin TJ (1998) Preemptive pain control in patients having laparoscopic hernia repair: a comparison of ketorolac and ibuprofen. Arch Surg 133/4: 432–437CrossRefGoogle Scholar
  9. Moore N, van Gause E, Le Parc JM,Wall R, Schneid H, Farhan M, Verriere F, PÜelen F (1999) The PAIN study: paracetanol, aspirin and ibuprofen new toleranbility study - a large-scale, randomised clinical trial comparing the tolerability of aspirin, ibuprofen and peracetanol for short-term analgesia. Clin Drug Invest 18: 89–98CrossRefGoogle Scholar
  10. Neupert W, Brugger R, Euchenhofer C et al. (1997) Effects of ibuprofen enantiomers and its coenzyme A thioesters on human Prostaglandin endoperoxide synthases. Br J Pharmacol 122/3: 487–492CrossRefGoogle Scholar
  11. Primack WA, Rahman SM, Pullman J (1997) Acute renal failure associated with amoxicillin and ibuprofen in an 11-year old boy. Correspondence. Pediatr Nephrol 1:125–126Google Scholar
  12. Ramachandran S, Giles PD, Hartland A (1997) Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment. BMJ 314 (7094): 1593PubMedCrossRefGoogle Scholar
  13. Scheuren N, Bang H, Münster T et al. (1998) Modulation of transcription factor NF-kappa B by enantiomer of the nonsteroidal drug ibuprofen. Br J Pharmacol 123/4: 645–652CrossRefGoogle Scholar
  14. Sivarajan M, Wasse L (1997) Perioperative acute renal failure associated with preoperative intake of ibuprofen. Correspondence. Anesthesiology 86/6: 1390–1392CrossRefGoogle Scholar
  15. Stoves J, Rosenberg K, Harnden P et al. (1998) Acute interstitial nephritis due to over-the-counter ibuprofen in a renal transplant recipent Nephrol Dial Transplant 13/1: 227–228Google Scholar
  16. Stratman NC; Carter DB; Sethy VH (1997) Ibuprofen: effect on inducible nitric oxide synthase. Brain Res Mol Brain Res 50/1–2:107–112CrossRefGoogle Scholar

Literatur bis 1996: → CD-ROM

  1. Anonymous (1997) Kontaktdermatif av ketoprofen. Lakartidningen 94/30–31: 2664–2665Google Scholar
  2. Badid C, Chambrier C, Aouifi A et al. (1997) Anti-inflammatoire non steroidien et inhibiteur de l’enzyme de conversion: association dangereuse en période postopératoire. Ann Fr Anesth Reanim 16/1: 55–57Google Scholar
  3. Bannwarth B, Lagrange F, Pehourcq F et al. (1999) (S)-Ketoprofen accumulation in premature neonates with renal failure who were exposed to the racemate during pregnancy. Br J Clin Pharmacol 47/4: 459–460Google Scholar
  4. de Miguel Diéz J, Ramos Martos A, Serrano Iglesias JA (1998) Agudizacíon asmática severa causada por la aplicación de ketoprofeno. Correspondence. Arch Bronconeumol 34/4: 224–225Google Scholar
  5. Grubb NG, Rudy DW, Brater DC et al. (1999) Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a >futile cycle< of elimination. Br J Pharmacol 48/4: 494–500Google Scholar
  6. Herrero FJ, Parrado A, Cervero F (1997) Central and peripheral actions of the NSAID ketoprofen on spinal cord nociceptive reflexes. Neuropharmacology 36/10: 14425–1431Google Scholar
  7. Jamali F, Lovlin R, Aberg G (1997) Bi-directional chiral inversion of ketoprofen in CD-1 mice. Chirality 9/1: 29–31CrossRefGoogle Scholar
  8. Krummel T, Dimitrov Y, Moulin B et al. (2000) Acute renal failure induced by topical ketoprofen. BMJ 320(7227): 93PubMedCrossRefGoogle Scholar
  9. Mazario J, Roza C, Herrero JF (1999) The NSAID dexketoprofen trometamol is as potent as mu-opioids in the depression of wind-up and spinal cord nociceptive reflexes in normal rats. Brain Res 816/2: 512–517CrossRefGoogle Scholar
  10. Mirande-Romero A, Gonzalez-LF (1999) The NSAID dexketoprofen trometamol is as potent as mu-opioids in the depression of wind-up and spinalGoogle Scholar
  11. Nikanne E, Kokki H, Tuovinen K (1997) I.v. perioperative ketoprofen in small children during adenoidectomy. Br J Anaesth 78/1: 24–27CrossRefGoogle Scholar
  12. Rudy AC, Liu Y, Brater C et al. (1998) Stereoselective pharmacokinetics and inversion of (R)-ketoprofen in healthy volunteers. J Clin Pharmacol 38/2S): 3S–10SCrossRefGoogle Scholar

Literatur bis 1996: → CD-ROM

  1. Burtscher M (1999) Höhenkopfschmerz: Epidemiologie, Pathophysiologie, Therapie und Prophylaxe. Wien Klin Wochenschr 111/20: 830–836Google Scholar
  2. Davies NM, Anderson KE (1997) Clinical pharmacokinetics of naproxen. Clin Pharmacokinet 32(4): 268–293PubMedCrossRefGoogle Scholar
  3. Davies NM, Roseth AG, Appleyard CB (1997) NO-naproxen vs.naproxen: ulzerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 1: 69–79CrossRefGoogle Scholar
  4. Khan LS, Chen M, Eaton R (1997) Over-the-counter naproxen sodium and esophageal injury. Correspondence. Ann Intern Med 126/12: 1006CrossRefGoogle Scholar
  5. Strom BL, Schinnar R, Bilker WB et al. (1997) Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen Arch Intern Med. 157: 2626–2631PubMedCrossRefGoogle Scholar
  6. Tracy TS, Marra C, Wrighton SA et al. (1997) Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation.Eur J Clin Pharmacol 52/4: 293–298CrossRefGoogle Scholar
  7. Vielpau C, Joubert HM, Hulet C (1999) Naproxen in the prevention of heterotopic ossification after total hip replacement. Clin Orthop Dec 369: 279–288CrossRefGoogle Scholar
  8. Zhang WY, Li Wan Pa A (1998) Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 105/7: 780–789Google Scholar

Literatur bis 1996: → CD-ROM

  1. Andreassen KH, Eldrup J, Hansen RI et al. (1999) Tiaprofenic acidinduced cystitis - three cases and a literatur review. Scand J Urol Nephrol 33/6: 408–410Google Scholar
  2. Crawford ML, Waller PC, Wood SM (1997) Severe cystitis associated with tiaprofenic acid. Br J Urol 79/4: 578–584Google Scholar
  3. Crew JP, Donat R, Roskeil D (1997) Bilateral ureteric obstruction secondary to the prolonged use of tiaprofenic acid. Br J Clin Pract 51/1: 59–6Google Scholar
  4. Gheyi SK, Robertson A, Atkinson PM (1999) Severe interstitial cystitis caused by tiaprofenic acid. J R Soc Med 92/1: 17Google Scholar
  5. Henley MJ, Harriss D, Bishop MC (1997) Cystitis associated with tiaprofenic acid: a survey of British and Irish urologists. Br J Urol 79/4: 585–587Google Scholar
  6. Lindquist M, Pettersson M, Edwards IR et al. (1997) How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. ADR Signals Analysis Project (ASAP) Team. Pharmacol Toxicol 80/5: 211–217Google Scholar
  7. Schou J, Jensen HL, Frimodt-Moller C (1999) Interstitial cystitis provoked by tiaprofenic acid. Scand J Urol Nephrol 33/6: 411–412Google Scholar
  8. van Gameren II, Gökemmeijer JD (1997) Cystitis and interstitial nephritis related to the use of tiaprofenic acid (Surgam). Neth J Med 51/6: 228–231Google Scholar

Literatur bis 1996: → CD-ROM

  1. Berg J, Fellier H, Christoph T et al. (1999) The analgesic NSAID lornoxicam inhibits cyclooxygenase (C0X)-1-/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res 48/7: 369–379CrossRefGoogle Scholar
  2. Masche UO, Rentsch KM, von Feiten A et al. (1999) Opposite effects of lornoxicam co-administration on phenprocoumon phar-macokinetics and pharmacodynamics. Eur J Clin Pharmacol 54/11: 857–864CrossRefGoogle Scholar
  3. Staunstrup H, Ovesen J, Larsen UT et al. (1999) Efficacy and tolerability of lornoxicam vs. tramadol in postoperative pain. J Clin Pharmacol 39/8: 834–841CrossRefGoogle Scholar

Literatur bis 1996: → CD-ROM

  1. Bosch HC, Sigmund R, Hettich M (1997) Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral Piroxicam. Curr Med Res Opin 14/1: 29–38CrossRefGoogle Scholar
  2. Calmels C, Dubost JJ, Jasmin-Lebrun C et al. (1999) A new case of NSAID-inducer infertility. Rev Rhum Engl Ed 66/3: 167–168Google Scholar
  3. Camilleri M, Pace JL (1998) Linear IgA bullous dermatosis induced by piroxicam. J Eur Acad Dermatol Venereol 1: 70–72CrossRefGoogle Scholar
  4. Laurett GR, Mattos AL, Lima IC (1997) Tramadol adn beta-cyclo-dextrin piroxicam: effective multimodal balanced analgesia for the intra- and postoperative period. Reg Anesth 3: 243–248CrossRefGoogle Scholar
  5. Müller P, Simon B (1997) Vergleichende endoskopische Untersuchungen zur gastroduodenalen Verträglichkeit von Piroxi-cam-beta-Cyclodextrin vs. Piroxicam. Z Rheumatol 56/2: 76–79Google Scholar
  6. Piperno M, Hellio le Graverand MP, Reboul P et al. (1997) Phos-pholipase A2 activity in herniated lumbar discs. Clinical correlations and inhibition by piroxicam. Spine 22/18:2061–2065CrossRefGoogle Scholar
  7. Selcuk E, Gomel M, Apaydin S et al. (1998) The postoperative analgesic efficacy and safety of piroxicam (FDDF) and naproxen sodium. Int J Clin Pharmacol Res 18/1: 21–29Google Scholar
  8. Supervía A, Pedro-Botet J, Nogués X et al. (1998) Piroxicam fasdissolving form vs. Diclofenac sodium in the treatment of acute renal colic: a double-blind controlled trial. Br J Urol 81/1: 27–30Google Scholar
  9. Varela P, Amorim I, Massa A et al. (1998) Piroxicam-beta-cyclodextrin and photosensitivity reactions. Contact Dermatitis 38/4: 229CrossRefGoogle Scholar

Literatur vor 1996: CD-ROM

  1. Aroca García MD, Líma Rodríguez C, Gallego Navarro MA et al. (1997) Alopecia secundaria a tenoxicam. Un efecto adverso no descrito? Correspondence. Aten Primaria 3: 157Google Scholar
  2. Colbert S, O’Hanlon DM, Chambers F et al. (1999) The effect of intravenous tenoxicam on pruritus in patients receiving epidural fentanyl. Anaesthesia 54/1: 76–80CrossRefGoogle Scholar
  3. Colbert ST, O’Hanlon DM, McDonnell C et al. (1998) Analgesia in day case breast biopsy - the value of pre-emptive tenoxicam. Can J Anaesth 45/3: 217–222Google Scholar
  4. Cook TM, Tuckey JP, Nolan JP (1997) Analgesia after day-case knee arthroscopy: double-blind study of intra-articular tenoxicam, intra-articular bupivacaine and placebo. Br J Anaesth 78/2: 163–168CrossRefGoogle Scholar
  5. Hoffmann V, Vercauteren M, Van Steenberge A et al. (1997) Intravenous regional anesthesia. Evaluation of 4 different additives to prilocaine. Acta Anaesth Belg 48/2: 71–76Google Scholar
  6. Jones NC, Pugh SC (1996) The addition of tenoxicam to prilocaine for intravenous regional anaesthesia. Anaesthesia 51/5: 446–448CrossRefGoogle Scholar
  7. Katsinelos P, Katsos I, Patsiaoura K et al. (1997) Tenoxica-associated hepatic injury: a case report and review. Eur J Gastroenterol Hepatol 4: 403–406CrossRefGoogle Scholar
  8. Munro FJ, Young SJ, Broome IJ et al. (1998) Intravenous tenoxicam for analgesia following laparoscopic cholecystectomy. Anaesth Intensive Care 1: 56–60Google Scholar
  9. Ucok C (1997) Stereophotogrammetric assessment of the effect of tenoxicam on facial swelling subsequent to third molar surgery. Int J Oral Maxillofac Surg 5: 380–382CrossRefGoogle Scholar

Literatur bis 1996: → CD-ROM

  1. Apostolou T, Sotsiou F, Yfanti G et al. (1997) Acute renal failure induced by nimesulide in a patient suffering from temporal arteritis. Nephrol Dial Transplant 7: 1493–1496CrossRefGoogle Scholar
  2. de Almeida MA, Gaspar AP, Carvalho FS et al. (1997) Adverse reac-tions to acetaminophen, ASA, and NSAIDs in children: what alternatives? Allergy Asthma Proc 5: 313–318CrossRefGoogle Scholar
  3. Del Rosse A, Fradella G, Russo L et al. (1997) Pheochromocytoma crisis caused by contemporary ergotamine, caffeine, and nimesulide administration. Am J Med Sci 314/6: 396–398CrossRefGoogle Scholar
  4. Famaey JP (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res 46/11: 437–446CrossRefGoogle Scholar
  5. Gupta S, Velpandian T, Mathur P et al. (1998) Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmaeokinetie profile of nimesulide. Pharmacology 56/3: 137–143CrossRefGoogle Scholar
  6. McCormick PA, Kennedy F, Curry M et al. (1999) COX 2 inhibitor and fulminant hepatic failure. Research letter. Lancet 353 (9146): 44–41CrossRefGoogle Scholar
  7. Panara MR, Padovano R, Sciulli MG et al. (1998) Effects of nimesulide on constitutive and inducible Prostanoid biosynthesis in human beings. Clin Pharmacol Ther 63/6: 672–681CrossRefGoogle Scholar
  8. Peruzzi L, Gianoglio B, Porcellini MG et al. (1999) Neonatal endstage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic. Correspondence. Lancet 354 (9073): 265–266Google Scholar
  9. Rainsford (1999) Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rheumatology (Oxford) 38/S1: 4–10CrossRefGoogle Scholar
  10. Romero Gomez M, Nevado Santos M, Fobelo MJ et al. (1999) Hepatitis aguda pr nimesulida: descripeion de tres casos. Med Clin (Barc) 113/9: 357–358Google Scholar
  11. Taniguchi Y, Yokoyama K, Inui K et al. (1997) Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Eur J Pharmacol 330/2–3: 221–229CrossRefGoogle Scholar
  12. Van Steenbergen W, Peeters P, De Bondt J et al. (1998) Nimesulideinduced acute hepatitis: Evidence from six cases. J Hepatol 29/1: 135–141CrossRefGoogle Scholar
  13. Ventura MT, Cenci L, Giuliano G et al. (1999) Retrospective study of adverse reactions to non Steroid anti-inflammatory drugs (NSAIDs): predictive value of controlled challenge with alternative drugs. Immunopharmacol Immunotoxicol 21/3: 455–468CrossRefGoogle Scholar
  14. Wober W (1999) Comparative efficacy and safety of nimesulide and diclofenac in patients with acute Shoulder, and a metaanalysis of controlled studies with nimesulide. Rheumatology (Oxford) 38/S1: 33–38CrossRefGoogle Scholar

Literatur

  1. Hernández Bueno JA, de la Jara Díaz J, Seduno Cruz F et al. (1998) Effecto analésico antiespasmódico y seguridad del clonixinato de lisina y bromuro de L-butilhioscina en el tratamiento oral de la dismenorrea. Ginecol Obstet Mex 66: 35–39PubMedGoogle Scholar

Siehe CD-ROM

  1. Wasfi IA, Abdel Hadi AH, Zorbo O (1197) Pharmacokinetis of phenylutazone in camels. Am J Vet Res 58/6: 636–640PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Herman Hans Waldvogel
    • 1
  1. 1.La Forestière, PiolanSt. Paul en ChablaisFrankreich

Personalised recommendations